March 11, 2022 8:08am

Ceasefire talks between Russia and Ukraine could be helping markets to gain traction; although Thursday’s aftermarket was extremely weak, an indication

Pre-open indications: 3 SELL and 5 BUY indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Only the facts … I ask questions and note the indications of what could happen …

TGIF, can’t end soon enough

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +1.05% (347 points), S&P futures are UP +1.24% (+53 points) and NASDAQ futures are UP +1.54% (+210 points)

 

Stock futures rose in the pre-open ahead of Friday’s session

European markets inched higher

Asia-Pacific markets slipped continuing to keep investors cautious.

 

Henry’omics:

This week so far, the Dow is down 1.31% and headed for its fifth negative week in a row since May 2019, the S&P is down 1.60% and Nasdaq 1.38%.

“Russia’s invasion of Ukraine, and the subsequent barrage of Western economic sanctions against Moscow, has exacerbated price pressures that were already causing headaches for central bank policymakers.” <CNBC>

 

 

RegMed Investors’ (RMi) closing bell: “the algorithms beat me to the profit window.” … https://www.regmedinvestors.com/articles/12336

Ebb and flow –

·         March – 5 negative and 3 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  24 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context:

BUY:

Agenus (AGEN) closed up +$0.17 after Tuesday’s +$0.02 and Monday’s +$0.01 with a positive +$0.07 or +2.38% pre-open indication

Caribou Therapeutics (CRBU) closed down -$0.24 with a positive +$0.38 or +3.99% with a pre-open indication.

Cellectis SA (CLLS) closed up+$0.06 with a positive +$0.30 or +7.14% pre-open indication

CHRISPR Therapeutics (CRSP) closed up +$0.01 with a positive +$0.07 or +0.11% pre-open indication.

Intellia Therapeutics (NTLA) closed down -$0.08 with a positive +$2.05 or +3.11% pre-open indication.

 

SELL:

Ionis Pharmaceuticals (IONS) closed down -$0.16 after Wednesday’s +$0.98 with a negative -$0.67 or -2.02% pre-open indication.

Voyager Therapeutics (VYGR) closed down -$0.08 after Wednesday’s +$1.06 and Tuesday’s +$1.31 or +33.33% with a negative -$0.11 or -1.77% pre-open indication.

Sangamo Therapeutics (SGMO) closed down -$0.09 after Wednesday’s +$0.32 with a negative -$0.05 or -0.85% pre-open indication.

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed down Thursday -$0.63 with 488 shares traded after Wednesday’s -$0.26 with 1,225 shares traded, Tuesday’s flat (having been up +$0.14) with 1,142 shares traded, Monday’s +$0.29 with 399 shares traded and last Friday’s -$0.44 with 1,300 shares traded …

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …
  • BSTG is NOT going ANYWHERE without a cash infusion.

 

The BOTTOM LINE: I believe many of the oversold show buy signals but, usually reverse lower.

A shaky sector set-up within the market continues a correction as compared to January and February’s movement.

There is no clear trend, and no reason to make any BUYS - near, long but, mostly short.

If you want to make or break positions, consider taking partial or full profits at 10% or even 5%.

In this news-driven market, a headline could send stock prices soaring or plunging, with little confidence in the news or market move.

At some point, a clear market uptrend will take hold.  I am NOT waiting for a reversal it’s going to continue.

As I have stated yesterday, “bounce, baby, bounce”.

Earnings’ reporting on the horizon:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.